The combination of nivolumab with an interleukin-15 agonist was well tolerated with no dose-limiting toxicities in patients with metastatic non–small-cell lung cancer.
Pembrolizumab offered stable or improved measures of global health status and quality of life compared with chemotherapy in patients with previously treated advanced urothelial cancer.
Five-year results showed durable responses and long-term overall survival in a proportion of patients with pretreated advanced non–small-cell lung cancer who received nivolumab.
The FDA has granted a Breakthrough Therapy designation to the antibody-drug conjugate enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer.
Two new studies have found that some HER2-positive and triple-negative breast cancer patients can avoid sentinel lymph node biopsy after neoadjuvant systemic therapy.
Increases in resource use were not associated with improved survival or quality of care for patients with metastatic prostate cancer, but were associated with higher healthcare costs.
The rate of severe acute toxicity was relatively low in a study of radiosensitization with veliparib for patients with inflammatory or locally recurrent breast cancer.
Proton radiation therapy offers some reduced toxicity over IMRT in patients under the age of 65 with prostate cancer, but its cost is nearly double.
Interventions can improve sun protection behaviors, but this does not necessarily correlate with skin cancer/melanoma outcomes, according to a review for the USPSTF.
ASTRO has released new guidelines recommending hypofractionated whole-breast irradiation for women with breast cancer.